ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
VANFLYTA? Receives Approval in Japan americanpharmaceuticalreview
June 20, 2019Daiichi Sankyo announced the Ministry of Health, Labor and Welfare (MHLW) of Japan has approved VANFLYTA? (quizartinib), an oral FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detecte
Pharma Sources Insight January 2025
